Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Naunyn Schmiedebergs Arch Pharmacol
2010 May 01;3815:385-400. doi: 10.1007/s00210-010-0496-7.
Show Gene links
Show Anatomy links
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H, Bloehs R, Kisselbach J, Karle CA, Schweizer PA, Katus HA, Thomas D.
???displayArticle.abstract???
The antidepressant amoxapine has been linked to cases of QT prolongation, acute heart failure, and sudden death. Inhibition of cardiac hERG (Kv11.1) potassium channels causes prolonged repolarization and is implicated in apoptosis. Apoptosis in association with amoxapine has not yet been reported. This study was designed to investigate amoxapine effects on hERG currents, hERG protein trafficking, and hERG-associated apoptosis in order to elucidate molecular mechanisms underlying cardiac side effects of the drug. hERG channels were expressed in Xenopus laevis oocytes and HEK 293 cells, and potassium currents were recorded using patch clamp and two-electrode voltage clamp electrophysiology. Protein trafficking was evaluated in HEK 293 cells by Western blot analysis, and cell viability was assessed in HEK cells by immunocytochemistry and colorimetric MTT assay. Amoxapine caused acute hERG blockade in oocytes (IC(50) = 21.6 microM) and in HEK 293 cells (IC(50) = 5.1 microM). Mutation of residues Y652 and F656 attenuated hERG blockade, suggesting drug binding to a receptor inside the channel pore. Channels were mainly blocked in open and inactivated states, and voltage dependence was observed with reduced inhibition at positive potentials. Amoxapine block was reverse frequency-dependent and caused accelerated and leftward-shifted inactivation. Furthermore, amoxapine application resulted in chronic reduction of hERG trafficking into the cell surface membrane (IC(50) = 15.3 microM). Finally, the antidepressant drug triggered apoptosis in cells expressing hERG channels. We provide evidence for triple mechanisms of hERG liability associated with amoxapine: (1) direct hERG current inhibition, (2) disruption of hERG protein trafficking, and (3) induction of apoptosis. Further experiments are required to validate a specific pro-apoptotic effect mediated through blockade of hERG channels.
Becchetti,
A comment on ion channels as pharmacological targets in oncology.
2008, Pubmed
Becchetti,
A comment on ion channels as pharmacological targets in oncology.
2008,
Pubmed Coccaro,
Second generation antidepressants: a comparative review.
1985,
Pubmed Delgado,
Electrophysiological effects of amoxapine in untreated and in amoxapine-pretreated rat atria.
1986,
Pubmed Dennis,
hERG channel trafficking: novel targets in drug-induced long QT syndrome.
2007,
Pubmed Dorian,
Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview.
2000,
Pubmed Duncan,
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.
2007,
Pubmed Ficker,
Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG.
2003,
Pubmed Ficker,
Mechanisms of arsenic-induced prolongation of cardiac repolarization.
2004,
Pubmed González-Juanatey,
Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade.
2003,
Pubmed Guo,
Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines.
2009,
Pubmed Guo,
Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes.
2007,
Pubmed Hondeghem,
Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.
1990,
Pubmed Jo,
Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652.
2008,
Pubmed
,
Xenbase Kiehn,
Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
1999,
Pubmed
,
Xenbase Kiesecker,
Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels.
2006,
Pubmed
,
Xenbase Kinugawa,
Inhibitory actions of amoxapine, a tricyclic antidepressant agent, on electrophysiological properties of mammalian isolated cardiac preparations.
1988,
Pubmed Kudo,
A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs.
2007,
Pubmed Mahapatra,
Cardiovascular effects of polycyclic antidepressants.
1986,
Pubmed Milnes,
Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
2003,
Pubmed Mitcheson,
Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine.
2003,
Pubmed Mitcheson,
A structural basis for drug-induced long QT syndrome.
2000,
Pubmed
,
Xenbase Mosmann,
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
1983,
Pubmed Munger,
Amoxapine cardiotoxicity.
1988,
Pubmed Napolitano,
Torsade de pointes. Mechanisms and management.
1994,
Pubmed NULL,
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
2000,
Pubmed Ortiz,
Premature atrial contractions and amoxapine therapy: a case report.
1983,
Pubmed Paul,
Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.
2002,
Pubmed Rajamani,
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
2006,
Pubmed Redfern,
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
2003,
Pubmed Robertson,
Endocytic control of ion channel density as a target for cardiovascular disease.
2009,
Pubmed Roden,
Repolarization reserve: a moving target.
2008,
Pubmed Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase Satoh,
Role of poly(ADP-ribose) formation in DNA repair.
1992,
Pubmed Scherer,
Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin.
2008,
Pubmed
,
Xenbase Schumacher,
Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5.
2009,
Pubmed Smith,
Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells.
2002,
Pubmed Sørensen,
Acute myocardial failure following amoxapine intoxication.
1988,
Pubmed Spector,
Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
1996,
Pubmed
,
Xenbase Staudacher,
hERG: protein trafficking and potential for therapy and drug side effects.
2010,
Pubmed Takemasa,
Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.
2008,
Pubmed Teschemacher,
Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.
1999,
Pubmed Thomas,
The antipsychotic drug chlorpromazine inhibits HERG potassium channels.
2003,
Pubmed
,
Xenbase Thomas,
Doxazosin induces apoptosis of cells expressing hERG K+ channels.
2008,
Pubmed Thomas,
Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing.
2003,
Pubmed Thomas,
The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
2006,
Pubmed Thomas,
High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
2001,
Pubmed
,
Xenbase Thomas,
The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels.
2002,
Pubmed
,
Xenbase Thomas,
Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A.
1999,
Pubmed
,
Xenbase van der Heyden,
Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon?
2008,
Pubmed Viskin,
Long QT syndromes and torsade de pointes.
1999,
Pubmed Walker,
Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.
1999,
Pubmed Wang,
HERG K+ channel, a regulator of tumor cell apoptosis and proliferation.
2002,
Pubmed Wang,
Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
2007,
Pubmed Warmke,
A family of potassium channel genes related to eag in Drosophila and mammals.
1994,
Pubmed Wedin,
Relative toxicity of cyclic antidepressants.
1986,
Pubmed Witchel,
The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
2004,
Pubmed
,
Xenbase Witchel,
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.
2002,
Pubmed Witchel,
Psychotropic drugs, cardiac arrhythmia, and sudden death.
2003,
Pubmed Yeung,
Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation.
2008,
Pubmed Zitron,
Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone.
2004,
Pubmed
,
Xenbase
